CSIMarket
 
180 Life Sciences Corp  (ATNF)
Other Ticker:  
 
 
Price: $3.5000 $-0.08 -2.235%
Day's High: $3.67 Week Perf: -9.79 %
Day's Low: $ 3.40 30 Day Perf: -12.28 %
Volume (M): 65 52 Wk High: $ 51.30
Volume (M$): $ 228 52 Wk Avg: $13.36
Open: $3.52 52 Wk Low: $2.85



 Market Capitalization (Millions $) 28
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

180 Life Sciences Corp
180 Life Sciences Corp is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of inflammatory disorders, fibrosis, and pain. The company utilizes its proprietary platform technology to identify and target key biological pathways involved in these conditions.

180 Life Sciences Corp aims to develop therapies that can provide much-needed relief to patients suffering from chronic inflammatory diseases such as fibrosis, arthritis, and multiple sclerosis. The company's approach involves utilizing anti-TNF therapies to target the TNF-alpha receptor, a key mediator of inflammation.

The company also seeks to address the high unmet medical need for non-opioid pain relief options by developing therapies that target the TRPV1 receptor, which plays a crucial role in pain signaling. These therapies have the potential to provide effective pain management without the risk of addiction associated with opioid medications.

180 Life Sciences Corp's pipeline includes several investigational drug candidates that have shown promising results in preclinical and early clinical studies. The company is focused on advancing these candidates through further clinical development and regulatory approval processes.

Overall, 180 Life Sciences Corp is dedicated to improving the lives of patients suffering from inflammatory disorders, fibrosis, and pain by developing innovative and effective therapies.


   Company Address: 3000 El Camino Real Bldg. 4 Palo Alto 94306 CA
   Company Phone Number: 507-0669   Stock Exchange / Ticker: NASDAQ ATNF
   ATNF is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

180 Life Sciences Reinstated: Nasdaq Compliance Ensures Continued Growth and Investor Confidence

Published Thu, Mar 14 2024 12:30 PM UTC

180 Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement, Ensuring Continued Listing on the Exchange
In a promising development for 180 Life Sciences Corp., the biotechnology company has successfully regained full compliance with the minimum bid price requirement of the Nasdaq Stock Market. This achievement ensures the company's continued listing on...

Shares

180 Life Sciences Energizes Market with Reverse Stock Split Announcement

Published Mon, Feb 26 2024 12:00 PM UTC

Innovative Biotech Company 180 Life Sciences Announces Reverse Stock Split
180 Life Sciences Corp. (NASDAQ: ATNF) has made a significant announcement that has caught the attention of investors and industry professionals alike. The Palo Alto-based company has revealed its plans to conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-...

Stock Market Announcement

180 Life Sciences Corp. Initiates Review of Strategic Alternatives to Unleash Value and Drive Growth

Published Tue, Nov 28 2023 2:00 PM UTC



PALO ALTO, Calif., Nov. 28, 2023 ? 180 Life Sciences Corp. (NASDAQ: ATNF), a leading biotechnology company, recently announced that its Board of Directors has commenced a comprehensive evaluation process to explore various strategic alternatives. These alternatives aim to unlock and maximize shareholder value. The Company will rely on the guidance of financial and ...

180 Life Sciences Corp

180 Life Sciences Corp Releases Impressive Third Quarter 2023 Financial Results, Dominating the Major Pharmaceutical Preparations Industry

Financial News Report:
In the recent July to September 30, 2023 reporting cycle, investors had not anticipated any significant changes in revenue for 180 Life Sciences Corp. However, shareholders were concerned about the company's operating deficit, which stood at $-3.538187 million during the same period. This figure surpasses the operating deficit reported in the third quarter of 2022, which was $-4.055152 million. The operating deficit is an important indicator of the company's financial health.
As an emerging growth company like 180 Life Sciences Corp continues to develop its business model, it becomes crucial for the company to operate economically in order to progress to the next stage. Encouragingly, the company has managed to reduce its diminishing returns from $-21.487 million in the third quarter of 2022 to $-10.266 million in the current reporting period. This improvement may assist 180 Life Sciences Corp on its journey to becoming a prominent player in the industry.

180 Life Sciences Corp

180 Life Sciences Corp Delivers Impressive Turnaround in Jun 30, 2023 Report, Overcoming $-3.68298 Million Operating Shortfall


Introduction
The stock market is always filled with surprises and fluctuations. Investors constantly analyze companies' financial reports and forecasts to gain insights into their future performance. One such company that caught the attention of market participants is 180 Life Sciences Corp (ATNF). Despite no anticipated modifications at the top-line, ATNF's operating shortfall revealed interesting insights during the April to June 30, 2023 reporting cycle.
Operating Shortfall Improvement
ATNF's operating shortfall for the period was at $-3.68298 million, a significant improvement from the corresponding period a year earlier, where it stood at $-4.521848 million. This improvement in operating shortfall has led to increased confidence among market participants regarding ATNF's potential. Although the company might be in an emerging situation, it is essential for them to nurture and expand their business model promptly while maintaining a strong liquidity position.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com